Docetaxel in combination with either cisplatin (DC) or gemcitabine (DG) in unresectable non-small sell lung carcinoma (NSCLC)

Docetaxel in combination with either cisplatin (DC) or gemcitabine (DG) in unresectable non-small sell lung carcinoma (NSCLC) - Docetaxel in combination with either cisplatin (DC) or gemcitabine (DG) in unresectable non-small sell lung carcinoma (NSCLC)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000310

Enrollment

150

Registered

2006-01-23

Start date

2002-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small sell lung carcinoma (NSCLC)

Interventions

The DC arm: Doc(60mg/m2) day1 CDDP(80mg/m2) day1 Every 3 to 4 weeks The DG arm: Doc(60mg/m2) day8 Gem(800mg/m2) day1,8 Every 3 to 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically or cytologically proven NSCLC 2.Stage IIIB or IV 3.Measurable lesions by RECIST 4.No prior therapy 5.PS(ECOG) 0 or 1 6.Expected survival of more than 3 months 7.Preserved organ functions 8.Age of 20 to 75-year old 9.Written IC

Exclusion criteria

Exclusion criteria: 1.Proven or suspected infections diseases 2.Interstitial pneumonia (pulmonary fibrosis) manifested with chest radiogram and symptoms 3.Uncontrolable complications of heart, liver, DM, bleeding, etc. 4.Peripheral neuropathy of grade 2 or severer 5.Pleural fluid requiring treatment 6.Pericardial fluid 7.Symptomatic brain metastasis 8.Active concomitant malignancy 9.Pregnancy, breast feeding or wish of future bearing 10.History of drug allergy 11.Myocardial infarction within 3 months 12.Requirement of emergency radiotherapy 13.Other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Survival (1-year survival rate) Toxicity	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026